Dabur India (DABUR) Q4 96/97 earnings summary

Executive summary

• FY97 turnover including other income was Rs 721.41 crore vs Rs 577.95 crore; profit after tax was Rs 42.90 crore vs Rs 34.41 crore.

• Operations expanded across consumer products, food, pharmaceuticals and exports, alongside significant manufacturing and distribution investments.

Financial highlights

• Sales less returns were Rs 706.81 crore vs Rs 561.78 crore; profit before tax was Rs 42.57 crore vs Rs 41.33 crore.

• Profit after tax included a Rs 1.51 crore write-back of earlier-year tax provision; current-year tax provision was Rs 1.15 crore.

• Export sales were Rs 91.54 crore vs Rs 69.02 crore; export growth was reported at 33%.

Outlook and guidance

• A new Baddi unit for Chyawanprash, Janma Ghunti, Lal Tail and other Ayurvedic medicines was expected to begin production during FY98.

• Food and pharmaceutical formulation units were planned for expansion and modernisation in FY98; new joint ventures were also expected to begin commercial production.

• Nepal operations planned an ~Rs 18 crore expansion and modernisation programme, including HDPE containers, fruit juice expansion and a horticulture nursery.